Compare PRTC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTC | BNTC |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.3M | 411.4M |
| IPO Year | N/A | 2020 |
| Metric | PRTC | BNTC |
|---|---|---|
| Price | $17.42 | $11.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.67 |
| AVG Volume (30 Days) | 14.7K | ★ 79.6K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.50 | $9.85 |
| 52 Week High | $19.92 | $17.15 |
| Indicator | PRTC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 43.68 |
| Support Level | $16.67 | $9.91 |
| Resistance Level | $18.70 | $13.40 |
| Average True Range (ATR) | 0.76 | 0.68 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 30.55 | 38.12 |
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.